Labetuzumab is a humanized anti-carcinoembryonic antigen (CEA) monoclonal antibody with antineoplastic activity. Labetuzumab has been used as an adjuvant treatment for colorectal cancer.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.